The full content of Annals is available to subscribers

Subscribe/Learn More  >
Original Research |

Efficacy and Safety of Controlled-Release Niacin in Dyslipoproteinemic Veterans

David R. Gray, PharmD; Timothy Morgan, MD; Steven D. Chretien, PharmD; and Moti L. Kashyap, MD
[+] Article, Author, and Disclosure Information

From the Long Beach Veterans Affairs Medical Center and the University of California, Irvine, California. Requests for Reprints: David R. Gray, PharmD, Veterans Affairs Medical Center RF 119, 5901 East Seventh Street, Long Beach, CA 90822. Acknowledgments: The authors thank Kim Seto, BS, and Katie Paik, BS, for their assistance in data collection. Grant Support: In part by a grant from Upsher-Smith Laboratories.

Copyright ©2004 by the American College of Physicians

Ann Intern Med. 1994;121(4):252-258. doi:10.7326/0003-4819-121-4-199408150-00003
Text Size: A A A

Objective: To evaluate the safety and efficacy of controlled-release niacin in patients with hyperlipoproteinemia.

Design: A retrospective cohort study.

Setting: A Department of Veterans Affairs Medical Center.

Patients: A consecutive sample of 969 predominantly elderly male veterans treated for dyslipoproteinemia with controlled-release niacin between October 1988 and October 1991.

Main Outcome Measures: Primary outcomes were lipid levels and lipoprotein cholesterol response, alterations in levels of hepatic enzymes and blood chemistry test results, and characterization of niacin-induced hepatotoxicity abstracted from the patient's medical, laboratory, and pharmacy records.

Results: 93% (896 of 969) of the cohort was evaluable. Patients (age, 61.7 years [9.4 years], mean [SD]) were treated for 1 to 36 months (13.0 months [9.7 months]) with an average maintenance dose of 1.67 g/d (0.8 g/d). Niacin was discontinued in 48.5% (435 of 896) of the patients primarily because of adverse effects. Poor glycemic control led to discontinuation in 40.6% (43 of 106) of the patients with diabetes mellitus. The lipoprotein response was dose-related and favorable (levels of total cholesterol, −19.1%;low-density lipoprotein cholesterol, −24.0%;high-density lipoprotein cholesterol, +5.7%; and triglycerides, −32.5%).Statistically but not clinically meaningful dose-related increases were seen in levels of liver enzymes and serum glucose (aspartate aminotransferase, +29%; alanine aminotransferase, +23%; alkaline phosphatase, +25%; and glucose, +7%; P = 0.0001). Twenty of 896 (2.2%) and 42 of 896 (4.7%) patients met biochemical criteria for probable and for possible or probable niacin-induced hepatotoxicity, respectively. Predisposing factors included high dose, alcohol use, preexisting liver disease, and concurrent oral sulfonylurea therapy.

Conclusions: Controlled-release niacin is effective in treating dyslipoproteinemia in selected middle-aged and elderly veterans, but approximately one half of patients discontinued the drug because of adverse effects or other causes including noncompliance. Niacin should be avoided in patients with hepatic dysfunction or a history of liver disease, patients with diabetes mellitus, and patients who abuse alcohol. Because controlled-release niacin seems to be more potent than crystalline niacin, product substitution without dose adjustment should be avoided.


niacin ; veterans


Grahic Jump Location
Figure 1.
The relation between the controlled-release niacin dose and the plasma lipoprotein cholesterol response based on percentage change.

HDLC = high-density lipoprotein cholesterol; LDLC = low-density lipoprotein cholesterol; TC = total cholesterol; and TG = triglycerides.

Grahic Jump Location
Grahic Jump Location
Figure 2.
The relation between the controlled-release niacin dose and the percentage change in levels of liver enzymes.

AP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; and GGT = γ-glutamyl transferase.

Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Nicotinamide and phosphate homeostasis in chronic kidney disease. Curr Opin Nephrol Hypertens 2016;25(4):285-91.
Statin Intolerance: A Literature Review and Management Strategies. Prog Cardiovasc Dis Published online Aug 3, 2016;
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.